Pharsight

Drugs that contain Defibrotide Sodium

1. Defitelio patents expiration

DEFITELIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(8 years from now)

US11085043 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(8 years from now)

US11746348 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-112) Mar 30, 2023
Orphan Drug Exclusivity(ODE) Mar 30, 2023
New Chemical Entity Exclusivity(NCE) Mar 30, 2021

NCE-1 date: 30 March, 2020

Market Authorisation Date: 30 March, 2016

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DEFITELIO family patents

Family Patents